Paediatric Diseases Working Party (PDWP)
Haemoglobinopathies Working Party (HWP)
Study type:
Study number:
8417030_2
Type of treatment:
Allogeneic
Diseases:
Other non-malignant disorders
Short title:
Primary objective:
To establish the impact of major, minor and bidirectional AB0 MM in the setting of allogeneic HSCT in pediatric patients
Key inclusion criteria:
Pediatric patients transplanted for hemoglobinopathies, thalassemia and SCD, in comparison with malignant disease
Country:
All EBMT member countries
Principal investigator:
Katharina Kleinschmidt
EBMT Study coordinator:
Arnaud Dalissier
Study coordinator email:
arnaud.dalissier@ebmt.org
EBMT Study Unit:
Paris Study Unit
Reason for processing personal data:
Patients’ data is needed to be able to identify the patient and calculate age at any time (impact on SAEs and response to clinical medications). Health care personal data is part of the CV collected for evidence of proper qualification for running the trial.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Study Specific Questionnaire (MED-C)
Recipients who may access the data:
Paris Study Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results